Postoperatif bulantı ve kusma

Yıl 2018, Cilt: 1 Sayı: 1, 1 - 6, 31.12.2018

Demet Laflı Tunay , Murat Türkeün Ilgınel

Öz

Postoperatif bulantı ve kusma günümüzde (POBK) yaygın bir cerrahi komplikasyon olmaya devam etmektedir. Özellikle günübirlik cerrahi hastalarının erken taburcu edilmesinde engelleyici bir faktördür ve beklenmeyen hastane başvurularının önde gelen bir nedenidir. POBK potansiyel hastane başvuruları, uzamış hemşirelik hizmetleri gibi sağlık giderlerinin miktarını artıran durumlara yol açabilir; ayrıca hasta memnuniyetsizliği ile de ilişkilidir. POBK’nın tedavisinde günümüzde pek çok farklı sınıftan ajan bulunmakla birlikte tedavisi POBK’nın önlenmesinden sıklıkla daha zor ve daha az etkindir. Bu sebeple risk altındaki hastalarda antiemetik profilaksisi mümkün olan en kısa sürede başlatılmalıdır.

Anahtar Kelimeler

postoperatif bulantı ve kusma, profilaksi, kombine tedavi

Kaynakça

• 1. Macario A, Weinger M, Carney S, et al. Which clinical anesthesia outcomes are important to avoid? The perspective of patients. Anesth Analg. 1999;89:652-8.
• 2. Fortier J, Chung F, Su J. Unanticipated admission after ambulatory surgery--a prospective study. Can J Anaesth. 1998;45:612-9.
• 3. Hill RP, Lubarsky DA, Phillips-Bute B, et al. Cost-effectiveness of prophylactic antiemetic therapy with ondansetron, droperidol, or placebo. Anesthesiology. 2000;92:958-67.
• 4. Carpenter DO. Neural mechanisms of emesis. Can J Physiol Pharmacol. 1990;68:230-6.
• 5. Hornby PJ. Central neurocircuitry associated with emesis. Am J Med. 2001;111 Suppl 8A:106S-112S.
• 6. Malagelada J-R, Malagelada C. Nausea and vomiting. In: Sleisenger and Fordtran's Gastrointestinal Disease, 10th ed, Feldman M, Freidman LS, Brandt LJ (Eds). WB Saunders, Philadelphia, 2015
• 7. Becker DE. Nausea, vomiting, and hiccups: a review of mechanisms and treatment. Anesth Prog. 2010;57:150-6.
• 8. Spiller R. Recent advances in understanding the role of serotonin in gastrointestinal motility in functional bowel disorders: alterations in 5-HT signalling and metabolism in human disease. Neurogastroenterol Motil. 2007;19 Suppl 2:25-31.
• 9. Horn CC, Wallisch WJ, Homanics GE, et al. Pathophysiological and neurochemical mechanisms of postoperative nausea and vomiting. Eur J Pharmacol. 2014;722:55-66.
• 10. Bountra C, Gale JD, Gardner CJ, et al. Towards understanding the aetiology and pathophysiology of the emetic reflex: novel approaches to antiemetic drugs. Oncology. 1996;53 Suppl 1:102-9.
• 11. Mitchelson F. Pharmacological agents affecting emesis. A review (Part I). Drugs. 1992;43:295-315.
• 12. Cohen MM, Duncan PG, DeBoer DP, et al. The postoperative interview: assessing risk factors for nausea and vomiting. Anesth Analg. 1994;78:7-16.
• 13. Apfel CC, Läärä E, Koivuranta M, et al. A simplified risk score for predicting postoperative nausea and vomiting: conclusions from cross-validations between two centers. Anesthesiology. 1999;91:693-700.
• 14. Koivuranta M, Läärä E, Snåre L, et al. A survey of postoperative nausea and vomiting. Anaesthesia. 1997;52:443-9.
• 15. Kranke P, Eberhart LH, Toker H, et al. A prospective evaluation of the POVOC score for the prediction of postoperative vomiting in children. Anesth Analg. 2007;105:1592-7.
• 16. Apfel CC, Heidrich FM, Jukar-Rao S, et al. Evidence-based analysis of risk factors for postoperative nausea and vomiting. Br J Anaesth. 2012;109:742-53.
• 17. Sinclair DR, Chung F, Mezei G. Can postoperative nausea and vomiting be predicted? Anesthesiology. 1999;91:109-18.
• 18. da Silva HB, Sousa AM, Guimarães GM, et al. Does previous chemotherapy-induced nausea and vomiting predict postoperative nausea and vomiting? Acta Anaesthesiol Scand. 2015;59:1145-53.
• 19. Tramèr M, Moore A, McQuay H. Omitting nitrous oxide in general anaesthesia: meta-analysis of intraoperative awareness and postoperative emesis in randomized controlled trials. Br J Anaesth. 1996;76:186-93.
• 20. Miller AD. Central mechanisms of vomiting. Dig Dis Sci. 1999;44:39S-43S.
• 21. Clissold SP, Heel RC. Transdermal hyoscine (Scopolamine). A preliminary review of its pharmacodynamic properties and therapeutic efficacy. Drugs. 1985;29:189-207.
• 22. Tramer MR, Moore RA, Reynolds DJ, et al. A quantitative systematic review of ondansetron in treatment of established postoperative nause and vomiting. BMJ. 1997;314:1088-92.
• 23. Lawrence KR, Nasraway SA. Conduction disturbances associated with administration of butyrophenone antipsychotics in the critically ill: a review of the literature. Pharmacotherapy. 1997;17:531-7.
• 24. Marder SR, Essock SM, Miller AL, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry. 2004;161:1334-49.
• 25. Grunberg SM, Gala KV, Lampenfeld M, et al. Comparison of the antiemetic effect of high-dose intravenous metoclopramide and high-dose intravenous haloperidol in a randomized double-blind crossover study. J Clin Oncol. 1984;2:782-7.
• 26. Gralla RJ, Itri LM, Pisko SE, et al. Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. N Engl J Med. 1981;305:905-9.
• 27. Bateman DN, Rawlins MD, Simpson JM. Extrapyramidal reactions with metoclopramide. Br Med J (Clin Res Ed). 1985;291:930-2.
• 28. Rao AS, Camilleri M. Review article: metoclopramide and tardive dyskinesia. Aliment Pharmacol Ther. 2010;31:11-9.
• 29. Benline TA, French J. Anti-emetic drug effects on cognitive and psychomotor performance: granisetron vs. ondansetron. Aviat Space Environ Med. 1997;68:504-11.
• 30. US Food and Drug Administration. Zofran (ondansetron): Drug Safety Communication - Risk of Abnormal Heart Rhythms. www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm272041.htm (Erişim tarihi Aralık 2018).
• 31. Saito R, Takano Y, Kamiya HO. Roles of substance P and NK(1) receptor in the brainstem in the development of emesis. J Pharmacol Sci. 2003;91:87-94.
• 32. Tattersall FD, Rycroft W, Francis B, et al. Tachykinin NK1 receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferrets. Neuropharmacology. 1996;35:1121-9.
• 33. Diemunsch P, Gan TJ, Philip BK, et al. Single-dose aprepitant vs ondansetron for the prevention of postoperative nausea and vomiting: a randomized, double-blind phase III trial in patients undergoing open abdominal surgery. Br J Anaesth. 2007;99:202-11.
• 34. Gan TJ, Apfel CC, Kovac A, et al. A randomized, double-blind comparison of the NK1 antagonist, aprepitant, versus ondansetron for the prevention of postoperative nausea and vomiting. Anesth Analg. 2007;104:1082-9.
• 35. Habib AS, Keifer JC, Borel CO, et al. A comparison of the combination of aprepitant and dexamethasone versus the combination of ondansetron and dexamethasone for the prevention of postoperative nausea and vomiting in patients undergoing craniotomy. Anesth Analg. 2011;112:813-8.
• 36. Wang JJ, Ho ST, Lee SC, et al. The use of dexamethasone for preventing postoperative nausea and vomiting in females undergoing thyroidectomy: a dose-ranging study. Anesth Analg. 2000;91:1404-7.
• 37. Henzi I, Walder B, Tramèr MR. Dexamethasone for the prevention of postoperative nausea and vomiting: a quantitative systematic review. Anesth Analg. 2000;90:186-94.
• 38. Levin DN, Dulberg Z, Chan AW, et al. A randomized-controlled trial of nabilone for the prevention of acute postoperative nausea and vomiting in elective surgery. Can J Anaesth. 2017;64:385-95.
• 39. Maxwell LG, Kaufmann SC, Bitzer S, et al. The effects of a small-dose naloxone infusion on opioid-induced side effects and analgesia in children and adolescents treated with intravenous patient-controlled analgesia: a double-blind, prospective, randomized, controlled study. Anesth Analg. 2005;100:953-8.